Insider · CIK 0002042268
Stephen David Prior
Files at ANTX (AN2 Therapeutics, Inc.). First filing Jan 7, 2025, latest Jan 7, 2026.
In brief
Stephen David Prior files SEC Form 4 as officer at ANTX (AN2 Therapeutics, Inc.). Since Jan 7, 2025, Stephen David Prior has reported 0 open-market buys worth $0 and 3 open-market sells worth $10k, the latest filed on Jan 7, 2026.
A track record needs three past buys with six months of prices behind them; Stephen David Prior has 0, so none is measured yet.
The newest scored trade: sold $6,507 of ANTX on Jan 5, 2026, filed Jan 7, 2026, scored 30 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $7,379.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ANTX: AN2 Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | AN2 Therapeutics, Inc. | $6,507 6,462 shares | -10% | +2% from low-30% from high | |
| 23Weak | AN2 Therapeutics, Inc. | $872 765 shares | -1% | +14% from low-32% from high | |
| 30Weak | AN2 Therapeutics, Inc. | $2,721 2,029 shares | -6% | +42% from low-15% from high |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stock | -3,604 | $1.00 | $3,615 | 61,944 | Jan 7, 2026 |
| Jan 6, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stock | -2,858 | $1.01 | $2,892 | 59,086 | Jan 7, 2026 |
| Nov 4, 2025 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stock | -765 | $1.14 | $872 | 65,548 | Nov 6, 2025 |
| Feb 26, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +28,000 | $0.00 | $0 | 61,313 | Feb 28, 2025 |
| Feb 26, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +56,000 | $0.00 | $0 | 56,000 | Feb 28, 2025 |
| Jan 3, 2025 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stock | -2,029 | $1.34 | $2,721 | 33,313 | Jan 7, 2025 |
| Nov 4, 2024 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +10,125 | $0.00 | $0 | 35,342 | Nov 5, 2024 |
| Nov 4, 2024 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,250 | $0.00 | $0 | 20,250 | Nov 5, 2024 |
Questions about Stephen David Prior
Answered from the filings on this page, as of the latest one.
Is Stephen David Prior buying or selling?
In the last 12 months Stephen David Prior reported 0 open-market buys worth $0 and 2 open-market sells worth $7,379 on SEC Form 4; the latest was sold $6,507 of ANTX on Jan 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Stephen David Prior's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Stephen David Prior has 0.
Where does Stephen David Prior file Form 4?
Stephen David Prior has filed Form 4 at ANTX (AN2 Therapeutics, Inc.) as Chief Strategy Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.